Revised Invitation for Expression of Interest (EOI) for medicines against HIV infection and related diseases published

The 20th Invitation for Expression of Interest (EOI) for medicines against HIV infection and related diseases, is published with the following changes: 

A)  The following products were added to the Priority List:

• Cabotegravir, suspension for intramuscular injection, 600mg/3ml (200mg/ml)
• Cabotegravir, tablet, 30 mg

B)  The following products were deleted from the Priority List:

• Lamivudine tablet 300 mg
• Efavirenz tablet 400 mg

C)  Furthermore, the following products were removed from the Complementary List of non-priority ARV products:

• Nevirapine, tablet 200 mg
• Atazanavir, capsule 150 mg; 300 mg
• Raltegravir, tablet 400 mg
• Emtricitabine/Tenofovir disoproxil fumarate/Efavirenz, tablet 200 mg/300 mg/600 mg
• Lamivudine/Tenofovir disoproxil fumarate/Efavirenz, tablet 300 mg/300 mg/600 mg
• Lamivudine/Zidovudine/Nevirapine, tablet 150 mg/300 mg/200 mg; tablet 150 mg/250 mg/200 mg
• One FDC tablet of Lamivudine/Tenofovir disoproxil fumarate/, 300 mg/300 mg, co-packaged with two single tablets of Nevirapine 200 mg
• One FDC tablet of Emtricitabine/Tenofovir disoproxil fumarate, 200 mg/300 mg, co-packaged with two single tablets of Nevirapine 200 mg
• One FDC tablet of Lamivudine/Tenofovir disoproxil fumarate/, 300 mg/300 mg, co-packaged with one FDC tablet (heat stable) of Atazanavir/Ritonavir 300 mg/100 mg
• One FDC tablet of Emtricitabine/Tenofovir disoproxil fumarate, 200 mg/300 mg, co-packaged with one FDC tablet (heat stable) of Atazanavir/ Ritonavir 300 mg/100 mg
• One FDC tablet of Lamivudine/Tenofovir disoproxil fumarate/, 300 mg/300 mg, co-packaged with one single tablet of Atazanavir 300 mg and one single tablet (heat stable) of Ritonavir 100 mg
• One FDC tablet of Emtricitabine/Tenofovir disoproxil fumarate, 200 mg/300 mg, co-packaged with one single tablet of Atazanavir 300 mg and one single tablet (heat stable) of Ritonavir 100 mg